Playback speed
10 seconds
ACC 2024 Insights: Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound and Durable Reductions In APOC-3 and Triglycerides (TG) in Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results
By
ACC 2024 Insights
FEATURING
Daniel Gaudet
By
ACC 2024 Insights
FEATURING
Daniel Gaudet
56 views
April 16, 2024
Login to view comments.
Click here to Login